BioSpace News Archive

Jazz Pharmaceuticals plc announced the closing of its previously announced offering of $1.5 billion in aggregate principal amount of 4.375% senior secured notes due 2029 by Jazz Securities Designated Activity Company, a direct wholly owned subsidiary of the Company.

Personalis, Inc., a leader in advanced genomics for cancer, announced that its management team will present at the 2021 Bank of America Healthcare Conference on Thursday, May 13, 2021 at 5:00 p.m. Eastern Time.

Mirum Pharmaceuticals, Inc., announced that the company will report financial results for the quarter ended March 31, 2021 on Thursday, May 6, 2021.

Omnicell, Inc., a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced results for its first quarter ended March 31, 2021.

380,000 square feet of facilities envisioned as creative tech hub where leading software, engineering, and bioscience talent can solve key problems to accelerate the discovery of new antibody treatments

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2021.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2021 first quarter, which ended March 31, 2021, on Tuesday, May 11, 2021, after the market close.

SOLA Biosciences, LLC, today announced positive preclinical data in mice from a study designed to evaluate the efficacy of SOL-257, an innovative gene therapy candidate selectively targeting pathogenic TDP-43, which is found in approximately 97% of ALS patients.

Jaguar Health, Inc. (NASDAQ:JAGX) today announced the title of the abstract regarding patient outcomes associated with cancer therapy-related diarrhea by Napo Pharmaceuticals, Inc. Jaguars wholly owned subsidiary, and Napos collaborators that has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held virtually from June 4, 2021

Seagen Inc. (Nasdaq:SGEN) today announced the presentation of new data from its growing pipeline of marketed and investigational therapies at the virtual scientific program of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 4-8.